Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibandronate.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Ibandronate.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate.
Advertisement
Aclarubicin
Aclarubicin may increase the hypocalcemic activities of Ibandronate.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Ibandronate.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Ibandronate.
Advertisement
Aluminum
The serum concentration of Ibandronate can be decreased when it is combined with Aluminium.
Aluminum Hydroxide
The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.
Advertisement
Aluminum Magnesium Silicate
The serum concentration of Ibandronate can be decreased when it is combined with Almasilate.
Amikacin
Amikacin may increase the hypocalcemic activities of Ibandronate.
Amiodarone
Ibandronate may increase the QTc-prolonging activities of Amiodarone.
Anagrelide
Ibandronate may increase the QTc-prolonging activities of Anagrelide.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Ibandronate.
Arbekacin
Arbekacin may increase the hypocalcemic activities of Ibandronate.
Arsenic Trioxide
Ibandronate may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Ibandronate may increase the QTc-prolonging activities of Artemether.
Asenapine
Ibandronate may increase the QTc-prolonging activities of Asenapine.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.
Azithromycin
Ibandronate may increase the QTc-prolonging activities of Azithromycin.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Ibandronate.
Bedaquiline
Ibandronate may increase the QTc-prolonging activities of Bedaquiline.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Ibandronate.
Bismuth Subcitrate
The serum concentration of Ibandronate can be decreased when it is combined with Bismuth Subcitrate.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Ibandronate.
Calcium Acetate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.
Calcium Carbonate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.
Calcium Chloride
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.
Calcium Chloride Anhydrous
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.
Calcium Citrate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Citrate.
Calcium Glubionate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.
Calcium gluceptate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.
Calcium Gluconate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.
Calcium Lactate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate.
Casein Allergenic Extract
The serum concentration of Ibandronate can be decreased when it is combined with Casein.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate.
Ceritinib
Ibandronate may increase the QTc-prolonging activities of Ceritinib.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Ibandronate.
Chlorpromazine
Ibandronate may increase the QTc-prolonging activities of Chlorpromazine.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ibandronate.
Ciprofloxacin
Ibandronate may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Ibandronate may increase the QTc-prolonging activities of Cisapride.
Citalopram
Ibandronate may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Ibandronate may increase the QTc-prolonging activities of Clarithromycin.
Clofezone
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Ibandronate.
Clozapine
Ibandronate may increase the QTc-prolonging activities of Clozapine.
Crizotinib
Ibandronate may increase the QTc-prolonging activities of Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Ibandronate.
Daunorubicin
Daunorubicin may increase the hypocalcemic activities of Ibandronate.
Deferasirox
The risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.
Dexlansoprazole
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Ibandronate.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.
Dihydrostreptomycin
Dihydrostreptomycin may increase the hypocalcemic activities of Ibandronate.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.
Disopyramide
Ibandronate may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Ibandronate may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Ibandronate may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Ibandronate may increase the QTc-prolonging activities of Domperidone.
Doxorubicin
Doxorubicin may increase the hypocalcemic activities of Ibandronate.
Doxorubicin Hydrochloride
Doxorubicin may increase the hypocalcemic activities of Ibandronate.
Dronedarone
Ibandronate may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Ibandronate may increase the QTc-prolonging activities of Droperidol.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Ibandronate.
Eliglustat
Ibandronate may increase the QTc-prolonging activities of Eliglustat.
Epirubicin
Epirubicin may increase the hypocalcemic activities of Ibandronate.
Erythromycin
Ibandronate may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Ibandronate may increase the QTc-prolonging activities of Escitalopram.
Esomeprazole
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Ibandronate.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ibandronate.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Ibandronate.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibandronate.
Flecainide
Ibandronate may increase the QTc-prolonging activities of Flecainide.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Ibandronate.
Fluoxetine
Ibandronate may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Ibandronate may increase the QTc-prolonging activities of Flupentixol.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate.
Framycetin
Framycetin may increase the hypocalcemic activities of Ibandronate.
Gadobenate
Ibandronate may increase the QTc-prolonging activities of Gadobenic acid.
Gemifloxacin
Ibandronate may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Ibandronate may increase the QTc-prolonging activities of Gemifloxacin.
Gentamicin
Gentamicin may increase the hypocalcemic activities of Ibandronate.
Goserelin
Ibandronate may increase the QTc-prolonging activities of Goserelin.
Granisetron
Ibandronate may increase the QTc-prolonging activities of Granisetron.
Haloperidol
Ibandronate may increase the QTc-prolonging activities of Haloperidol.
Hydrotalcite
The serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibandronate.
Ibutilide
Ibandronate may increase the QTc-prolonging activities of Ibutilide.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.
Idarubicin
Idarubicin may increase the hypocalcemic activities of Ibandronate.
Iloperidone
Ibandronate may increase the QTc-prolonging activities of Iloperidone.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Ibandronate.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.
Iron Sucrose
The serum concentration of Ibandronate can be decreased when it is combined with Iron saccharate.
Kanamycin
Kanamycin may increase the hypocalcemic activities of Ibandronate.
kanamycin A
Kanamycin may increase the hypocalcemic activities of Ibandronate.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Ibandronate.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.
Lansoprazole
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Ibandronate.
Lenvatinib
Ibandronate may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Ibandronate may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Ibandronate may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Ibandronate may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Ibandronate may increase the QTc-prolonging activities of Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ibandronate.
Lopinavir
Ibandronate may increase the QTc-prolonging activities of Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibandronate.
Lumefantrine
Ibandronate may increase the QTc-prolonging activities of Lumefantrine.
Magnesium Hydroxide
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.
Magnesium Oxide
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.
Magnesium Salicylate
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate.
Magnesium Sulfate
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium sulfate.
Magnesium Trisilicate
The serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate.
Methadone
Ibandronate may increase the QTc-prolonging activities of Methadone.
Metrizamide
Metrizamide may increase the hypocalcemic activities of Ibandronate.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Ibandronate.
Moxifloxacin
Ibandronate may increase the QTc-prolonging activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Ibandronate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Ibandronate.
Neomycin
Neomycin may increase the hypocalcemic activities of Ibandronate.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate.
Netilmicin
Netilmicin may increase the hypocalcemic activities of Ibandronate.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.
Nilotinib
Ibandronate may increase the QTc-prolonging activities of Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ibandronate.
Ofloxacin
Ibandronate may increase the QTc-prolonging activities of Ofloxacin.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.
Omeprazole
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.
Ondansetron
Ibandronate may increase the QTc-prolonging activities of Ondansetron.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate.
Paliperidone
Ibandronate may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Ibandronate may increase the QTc-prolonging activities of Panobinostat.
Pantoprazole
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate.
Paromomycin
Paromomycin may increase the hypocalcemic activities of Ibandronate.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Ibandronate.
Pazopanib
Ibandronate may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Ibandronate may increase the QTc-prolonging activities of Pentamidine.
Perflutren
Ibandronate may increase the QTc-prolonging activities of Perflutren.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.
Pimozide
Ibandronate may increase the QTc-prolonging activities of Pimozide.
Pirarubicin
Pirarubicin may increase the hypocalcemic activities of Ibandronate.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.
Plicamycin
Plicamycin may increase the hypocalcemic activities of Ibandronate.
Primaquine
Ibandronate may increase the QTc-prolonging activities of Primaquine.
Procainamide
Ibandronate may increase the QTc-prolonging activities of Procainamide.
Promazine
Ibandronate may increase the QTc-prolonging activities of Promazine.
Propafenone
Ibandronate may increase the QTc-prolonging activities of Propafenone.
Quetiapine
Ibandronate may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Ibandronate may increase the QTc-prolonging activities of Quetiapine.
Quinidine
Ibandronate may increase the QTc-prolonging activities of Quinidine.
Quinine
Ibandronate may increase the QTc-prolonging activities of Quinine.
Rabeprazole
The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibandronate.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibandronate.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate.
Saquinavir
Ibandronate may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Ibandronate may increase the QTc-prolonging activities of Saquinavir.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Ibandronate.
Sisomicin
Sisomicin may increase the hypocalcemic activities of Ibandronate.
Sotalol
Ibandronate may increase the QTc-prolonging activities of Sotalol.
Spectinomycin
Spectinomycin may increase the hypocalcemic activities of Ibandronate.
Streptomycin
Streptomycin may increase the hypocalcemic activities of Ibandronate.
Streptozocin
Streptozocin may increase the hypocalcemic activities of Ibandronate.
Sucroferric Oxyhydroxide
The serum concentration of Ibandronate can be decreased when it is combined with Iron saccharate.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate.
Sulfisoxazole
Ibandronate may increase the QTc-prolonging activities of Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Ibandronate.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.
Telavancin
Ibandronate may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Ibandronate may increase the QTc-prolonging activities of Telithromycin.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate.
Tetrabenazine
Ibandronate may increase the QTc-prolonging activities of Tetrabenazine.
Thioridazine
Ibandronate may increase the QTc-prolonging activities of Thioridazine.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate.
Tobramycin
Tobramycin may increase the hypocalcemic activities of Ibandronate.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.
Toremifene
Ibandronate may increase the QTc-prolonging activities of Toremifene.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.
Tricalcium Phosphate
The serum concentration of Ibandronate can be decreased when it is combined with Calcium Phosphate.
Tromethamine
The serum concentration of Ibandronate can be decreased when it is combined with Tromethamine.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate.
Valrubicin
Valrubicin may increase the hypocalcemic activities of Ibandronate.
Vandetanib
Ibandronate may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
Ibandronate may increase the QTc-prolonging activities of Vemurafenib.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Ibandronate.
Ziprasidone
Ibandronate may increase the QTc-prolonging activities of Ziprasidone.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.
Zuclopenthixol
Ibandronate may increase the QTc-prolonging activities of Zuclopenthixol.
